Compare LRN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LRN | NAMS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 2.8B |
| IPO Year | 2007 | 2022 |
| Metric | LRN | NAMS |
|---|---|---|
| Price | $79.61 | $20.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 16 |
| Target Price | ★ $102.50 | $49.93 |
| AVG Volume (30 Days) | 878.3K | ★ 1.4M |
| Earning Date | 10-20-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 32.81 |
| EPS | ★ 1.45 | N/A |
| Revenue | ★ $917,734,000.00 | $22,503,000.00 |
| Revenue This Year | $2.10 | $30.15 |
| Revenue Next Year | $4.63 | $384.12 |
| P/E Ratio | $51.83 | ★ N/A |
| Revenue Growth | ★ 3.29 | N/A |
| 52 Week Low | $60.61 | $19.13 |
| 52 Week High | $103.67 | $42.21 |
| Indicator | LRN | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 40.84 |
| Support Level | N/A | $19.36 |
| Resistance Level | $86.33 | $22.29 |
| Average True Range (ATR) | 3.06 | 1.15 |
| MACD | -0.47 | 0.05 |
| Stochastic Oscillator | 11.86 | 24.37 |
Stride Inc is a technology company providing an educational platform to deliver proprietary and third-party curriculum, software systems, and educational services designed to facilitate individualized learning for students and adults throughout the U.S. The platform delivers products and services to attract, enroll, educate, track progress, and support students. It provides customized solutions to public and private schools, school districts, charter boards, employers, government agencies, and consumers. Its platform addresses two markets in the K-12 space: General Education and Career Learning, with products and services for the General Education market predominantly focused on core subjects for kindergarten through twelfth grade students.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.